Fri, Dec 19, 2014, 4:59 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • biglefthook_00 biglefthook_00 Oct 15, 2013 9:21 AM Flag

    Tuesday Oct 22

    New data from a Phase 1 clinical trial combining TH-302 and pazopanib (Investigator Sponsored Trial 4001) in patients with advanced solid tumors will be presented in a poster session on Tuesday, October 22 (Abstract #C61). Updated data from a Phase 1/2 clinical trial combining TH-302 and sunitinib (Study 410) in patients with renal cell carcinoma, gastrointestinal tumors, or pancreatic neuroendocrine tumors will be presented in a poster session on Monday, October 21 (Abstract #B77). Emerging preclinical research suggests that anti-angiogenic therapy may increase tumor hypoxia. These two clinical trials further characterize the potential of combining TH-302 with anti-angiogenic agents.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The more interesting presentation is the pre-clinical data of TH-302 in pancreatic cancer when combined with Gem & Abraxane. Abraxane was just approved after a Phase-III trial showing a 1.8 month improvement in OS when combined with Gem vs Gem alone (OS improved from 6.7 months to 8.5 months). In the xenograft/mouse studies, Gem+Abraxane showed a complete response rate of 50%, while the Gem+Abraxane+TH-302 generated a 100% complete rate. Obviously, these xenograft study results don't translate directly to the clinic (otherwise the 50% of the patients in the Abraxane+Gem Phase III trial would have had complete responses), but if TH-302 can double the OS impact, it would still be meaningful. I assume there will be a Phase II study of TH-302+Gem+Abraxane done over the next year, so that by the time the Gem+TH-302 Phase III study is done, they will have a clinical dosing regime in place allowing doctors to add Abraxane "off label", so they don't have to choose which combo to use.

    • So... load up or hold???

 
THLD
3.07-0.05(-1.60%)4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.